Skip to main content
SpringerLink
Log in

Current and Novel Agents for the Treatment of Cytomegalovirus Retinitis

  • Section 1: Cytomegalovirus Retiniti
  • Leading Article
  • Published:
Drugs in R & D Aims and scope Submit manuscript

Abstract

The incidence of cytomegalovirus (CMV) retinitis appears to be declining with improved treatment protocols for HIV and prophylaxis protocols for other high risk patients. Despite this, CMV retinitis remains a major cause of visual loss in patients who are severely immunocompromised. Treatment options are evolving in the light of viral resistance, newmethods of drug delivery, new drugs, and the increased potential for improvement of immune function that modern antiretroviral therapy provides. In this article, we review the changing options available for the management of CMV retinitis and discuss possible therapeutic agents for the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pepose JS, Holland GN, Nestor MS, et al. Acquired immune deficiency syndrome: pathogenic mechanisms of ocular disease. Ophthalmology 1985 April; 92 (4): 472–85

    PubMed  CAS  Google Scholar 

  2. Jacobson MA, O’Donnell JJ, Porteous D, et al. Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: prevalence, natural history, and response to ganciclovir therapy. Q J Med 1988; 67: 473–86

    PubMed  CAS  Google Scholar 

  3. Palella Jr FJ, Delaney KM, Moorman AC, The HIV Outpatients Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853–60

    Article  PubMed  Google Scholar 

  4. Noble S, Faulds D. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 1998 Jul; 56 (1): 115–46

    Article  PubMed  CAS  Google Scholar 

  5. Bailey TC. Prevention of cytomegalovirus disease. Semin Respir Infect 1993 Sep; 8 (3): 225–32

    PubMed  CAS  Google Scholar 

  6. Stocchi R, Wrad KN, Fanin R, et al. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplant. Haematologica 1999 Jan; 84 (1); 71–9

    Google Scholar 

  7. Vila A, Guirado LL, Balius A, et al. Acyclovir prophylaxis of cytomegalovirus disease in kidney transplant recipients. Transpl Proc 1999 Sep; 31 (6): 2335–6

    Article  CAS  Google Scholar 

  8. Wreghitt TG, Abel SJ, McNeil K, et al. Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recients. Transpl Int 1999; 12 (4): 254–60

    Article  PubMed  CAS  Google Scholar 

  9. Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Study Group. Lancet 1997 Dec 13; 350 (9093): 1729–33

    Article  PubMed  CAS  Google Scholar 

  10. Fishburne BC, Mitrani AA, Davis JL. Cytomegalovirus retinitis after cardiac transplantation. Am J Ophthalmol 1998 Jan; 125 (1): 104–6

    Article  PubMed  CAS  Google Scholar 

  11. Baumal CR, Levin AV, Read SE. Cytomegalovirus retinitis in immunosuppressed children. Am J Ophthalmol 1999 May; 127 (5): 550–8

    Article  PubMed  CAS  Google Scholar 

  12. Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992; 358: 160–2

    Article  PubMed  CAS  Google Scholar 

  13. Cole NL, Balfour Jr HH. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to aciclovir and ganciclovir. Diagn Microbiol Infect Dis 1987; 6: 255–61

    Article  PubMed  CAS  Google Scholar 

  14. Erice A, Jordan MC, Chace BA, et al. Ganciclovir treatment of cytomegalovirus disease in transplant recipient and other immunocompromised host. JAMA 1987; 257: 3082–7

    Article  PubMed  CAS  Google Scholar 

  15. Spector SA, Weingeist T, Pollard RB, et al. Arandomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patientswith AIDS. J Infect Dis 1993; 168: 557–63

    Article  PubMed  CAS  Google Scholar 

  16. Hardy D, Spector S, Polsky B, et al. Combination ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. Eur J Clin Microbiol Infect Dis 1994; 13 Suppl. 2: S34–40

    Article  Google Scholar 

  17. Eriksson B, Schinazi RF. Combinations of 3′-azido-3’deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication In vitro. Antimicrob Agents Chemother 1989; 33: 663–8

    Article  PubMed  CAS  Google Scholar 

  18. Wagstaff AJ, Bryson HM. Foscarnet: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994 Aug; 48 (2): 199–226

    Article  PubMed  CAS  Google Scholar 

  19. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Arch Intern Med 1995; 155: 65–74

    Article  Google Scholar 

  20. Studies of Ocular Complications of AIDS Research Group and the AIDS Clinical Trials Group. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial 4: visual outcomes. Ophthalmology 1994; 101: 1250–61

    Google Scholar 

  21. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992; 326: 213–20

    Article  Google Scholar 

  22. Kuppermann BD, Quiceno JI, Flores-Aguilar M, et al. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J Infect Dis 1993; 168: 1506–9

    Article  PubMed  CAS  Google Scholar 

  23. Holland GN, Schuller JD. Progression rates of CMV retinopathy in ganciclovir treated and untreated patients. Arch Ophthalmol 1982; 110: 1435–42

    Article  Google Scholar 

  24. Cantrill HL, Henry K, Melroe H, et al. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long-term results. Ophthalmology 1989; 96: 367–74

    PubMed  CAS  Google Scholar 

  25. Young SH, Morlet N, Heery S, et al. High dose intravitreal ganciclovir in the treatment of cytomegalovirus retinitis. Med J Aust 1992 Sept 21; 157 (6): 370–3

    PubMed  CAS  Google Scholar 

  26. Hodge WG, Lalond RG, Sampalis J, et al. Once weekly intraocular injections of ganciclovir for maintenance therapy of cytomegalovirus retinitis: clinical and ocular outcome. J Infect Dis 1996: 174: 393–6

    Article  PubMed  CAS  Google Scholar 

  27. Diaz-Llopis M, Espana E, Munoz G, et al. High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. Br J Ophthalmol 1994 Feb; 78 (2): 120–4

    Article  PubMed  CAS  Google Scholar 

  28. Spector SA. Current therapeutic challenges in the treatment of cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14 Suppl 1: S32–5

    Article  Google Scholar 

  29. Spector SA, Busch DF, Follansbee S, et al. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group. J Infect Dis 1995 Jun; 171 (6): 1431–7

    Article  PubMed  CAS  Google Scholar 

  30. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med 1995 Sep 7; 333 (10): 615–20

    Article  PubMed  CAS  Google Scholar 

  31. Danner SA, Matheron S. Cytomegalovirus retinitis in AIDS patients: a comparative study of intravenous and oral ganciclovir as maintenance therapy. AIDS 1996; 10 Suppl. 4: S7–11

    Google Scholar 

  32. Squires KE. Oral Ganciclovir for cytomegalovirus retinitis in patients with AIDS: results of two randomized studies. AIDS 1996 10 Suppl. 4: S13–8

    Google Scholar 

  33. Smith JJ, Pearson TA, Blandford DL, et al. Intravitreal sustainedrelease ganciclovir. Arch Ophthalmol 1992; 110: 255–8

    Article  PubMed  CAS  Google Scholar 

  34. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained release ganciclovir implant. Arch Ophthalmol 1994; 112: 1531–9

    Article  PubMed  CAS  Google Scholar 

  35. Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med 1997; 337: 83–90

    Article  PubMed  CAS  Google Scholar 

  36. McCluskey PJ, Shah R, Versace P. Outcomes of cytomegalovirus retinitis following the use of ganciclovir implants. Aust N Z J Ophthalmol 1998 Aug; 26 (3): 207–10

    Article  PubMed  CAS  Google Scholar 

  37. Lim JI, Wolitz RA, Dowling AH, et al. Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1999 Mar; 127 (3): 288–93

    Article  PubMed  CAS  Google Scholar 

  38. Kendle JB, Fan-Havard P. Cidofovir in the treatment of cytomegaloviral disease. Ann Pharmacother 1998 Nov; 32 (11): 1181–92

    Article  PubMed  CAS  Google Scholar 

  39. Snoeck R, Sakuma T, De Clercq E, et al. (S)-1-(3-hydroxy-2-phosphonyl methoxypropyl) cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 1988; 32: 1839–44

    Article  PubMed  CAS  Google Scholar 

  40. Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS: a randomized controlled trial. Ann Intern Med 1997; 126: 257–63

    PubMed  CAS  Google Scholar 

  41. Davis JL, Taskintuna I, Freeman WR, et al. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 1997; 115: 733–7

    Article  PubMed  CAS  Google Scholar 

  42. Kirsch LS, Arevalo JF, de la Paz EC, et al. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 1995; 102: 533–43

    PubMed  CAS  Google Scholar 

  43. Taskintuna I, Rahhal FM, Rao NA, et al. Adverse events and autopsy findings after intravitreous cidofovir (HPMPC) therapy in patients with acquired immune deficiency syndrome (AIDS). Ophthalmology 1997 Nov; 104 (11): 1827–36

    PubMed  CAS  Google Scholar 

  44. Azad RF, Driver VB, Tanaka K, et al. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob Agents Chemother 1993 Sept; 37 (9): 1945–54

    Article  PubMed  CAS  Google Scholar 

  45. Anderson KP, Fox MC, Brown-Driver V, et al. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediateearly RNA. Antimicrob Agents Chemother 1996 Sept; 40: 2004–11

    PubMed  CAS  Google Scholar 

  46. Muccioli C, Goldstein DA, Johnson DW, et al. Fomivirsen safety and efficacy in the treatment of CMV retinitis: phase 3, controlled, multicenter study comparing immediate versus delayed treatment [abstract]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago, 224

    Google Scholar 

  47. Hutcherson SL, Palestine AG, Cantrill HL, et al. Antisense oligonucleotide safety and efficacy for CMV retinitis in AIDS patients [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20; San Francisco, 204

    Google Scholar 

  48. Hutcherson S. Clinical antiviral activities. In: Crooke ST, editor. Antisense research and application. Berlin: Springer-Verlag, 1998: 445–462

    Chapter  Google Scholar 

  49. Marwick C. First ‘antisense’ drug will treat CMV retinitis. JAMA 1998 Sept 9; 280 (10): 871

    Article  PubMed  CAS  Google Scholar 

  50. Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998; 177: 1080–3

    Article  PubMed  CAS  Google Scholar 

  51. Whitley RJ, Jacobson MA, Friedberg DN, et al. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. Arch InternMed 1998 May 11; 158 (9): 957–69

    Article  CAS  Google Scholar 

  52. Jabs DA, Bolton SG, Dunn JP, et al. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol 1998; 126: 817–22

    Article  PubMed  CAS  Google Scholar 

  53. Zegans ME, Walton RC, Holland GN, et al. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1998 Mar; 125 (3): 292–300

    Article  PubMed  CAS  Google Scholar 

  54. Karavellas MP, Lowder CY, Macdonald C, et al. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch Ophthalmol 1998 Feb; 116 (2): 169–75

    PubMed  CAS  Google Scholar 

  55. Henderson HW, Mitchell SM. Treatment of immune recovery vitritis with local steroids. Br J Ophthalmol 1999 May; 83 (5): 540–5

    Article  PubMed  CAS  Google Scholar 

  56. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997; 349: 1443–5

    Article  PubMed  CAS  Google Scholar 

  57. Montaner J, Mellors J. Better salvage therapy for HIV-1 infection still needed. Lancet 1999 May 29; 353: 1857

    Article  PubMed  CAS  Google Scholar 

  58. Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the aciclovir prodrug valaciclovir after escalating single and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993; 54: 595–605

    Article  PubMed  CAS  Google Scholar 

  59. Lowance D, Neumayer HH, Legendre CM, International Valaciclovir Cytomegalovirus Prophylaxis Transplantation Study Group, et al. Valaciclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999; 340 (19): 1462–70

    Article  PubMed  CAS  Google Scholar 

  60. Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double- blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. J Infect Dis 1998 Jan; 177 (1): 48–56

    Article  PubMed  CAS  Google Scholar 

  61. Jabs DA, Enger C, Dunn JP, et al. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. J Infect Dis 1998 Mar; 177 (3): 770–3

    Article  PubMed  CAS  Google Scholar 

  62. Drew WL, Stempien MJ, Andrews J, et al. Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir. J Infect Dis 1999 Jun; 179 (6): 1352–5

    Article  PubMed  CAS  Google Scholar 

  63. Chou S, Guentzel S, Michels KR, et al. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995; 172: 239–42

    Article  PubMed  CAS  Google Scholar 

  64. Sullivan V, Biron KK, Talarico C, et al. Apoint mutation in the human cytomegalovirus DNApolymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob Agents Chemother 1993; 37: 19–25

    Article  PubMed  CAS  Google Scholar 

  65. Perez JL. Resistance to antivirals in human CMV mechanisms and clinical significance. Microbiologica 1997; 13 (3): 343–52

    Google Scholar 

  66. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 1999 Apr; 12 (2): 286–97

    PubMed  CAS  Google Scholar 

  67. Schürmann D, Bergmann MP, Grobusch M, et al. Lack of efficacy of cidofovir in treating AIDS-related cytomegalovirus retinitis after long-term treatment with ganciclovir. AIDS 1998; 12 (6): 678–9

    PubMed  Google Scholar 

  68. Martin DF, Kupperman BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. N Engl J Med 1999; 340 (14): 1063–70

    Article  PubMed  CAS  Google Scholar 

  69. Snoeck R, Andrei G, Schols D, et al. Activity of different antiviral drug combinations against human CMV replication in vitro. Eur J Clin Microbiol 1992; 11: 1144–55

    Article  CAS  Google Scholar 

  70. Jacobson MA, Wilson S, Stanley H, et al. Phase 1 study of combination therapy with intravenous cidofovir and oral ganciclovir for cytomegalovirus retinitis in patients with AIDS. Clin Infect Dis 1999 Mar; 28 (3): 528–33

    Article  PubMed  CAS  Google Scholar 

  71. Manischewitz JF, Quinnan Jr GV, Lane HC, et al. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication In vitro. Antimicrob Agents Chemother 1990; 34: 373–5

    Article  PubMed  CAS  Google Scholar 

  72. Markham A, Faulds D. Ganciclovir: an update if its therapeutic use in cytomegalovirus infection. Drugs 1994; 48 (3): 455–84

    Article  PubMed  CAS  Google Scholar 

  73. Jung D, Dorr A. Single dose pharmacokinetics of valganciclovir in HIV and CMV seropositive subjects. J Clin Pharmacol 1999 Aug; 39 (8): 800–4

    Article  PubMed  CAS  Google Scholar 

  74. Brown F, Banken L, Sywell K, et al. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV and CMV-seropositive volunteers. Clin Pharmacokinet 1999 Aug; 37 (2): 167–76

    Article  PubMed  CAS  Google Scholar 

  75. Field AK, Pari GS, Martin RR. GEM132 — an antisense drug for the treatment of CMV. Int Antiviral New 1997; 5: 219–22

    Google Scholar 

  76. Koszalka GW, Chamberlain SD, Harvey RJ, et al. Benzimidazoles for the treatment of human cytomegalovirus. Antiviral Res 1996; 30: 43

    Google Scholar 

  77. Drew WL, Lalezari JP, Wang LH, et al. In vivo anti-CMV activity and safety of oral 1263W94 in HIV-infected subjects with asymptomatic CMV shedding. Antiviral Res 1998; 37: 70

    Google Scholar 

  78. Chen S-F, Perrella FW, Behrens DL, et al. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium. Cancer Res 1992; 52: 3521–7

    PubMed  CAS  Google Scholar 

  79. Wachsman M, Hamzeh FM, Assadi NB, et al. Antiviral activity of inhibitors of pyrimidine de-novo biosynthesis. Antiviral Chem Chemother 1996; 7: 7–13

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Ophthalmology, Institute of Ophthalmology, London and Moorfields Eye Hospital, 11-43 Bath Street, London, EC1V 9EL, England

    Toks Akerele & Susan Lightman

Authors
  1. Toks Akerele
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan Lightman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Akerele, T., Lightman, S. Current and Novel Agents for the Treatment of Cytomegalovirus Retinitis. Drugs R&D 2, 289–297 (1999). https://doi.org/10.2165/00126839-199902050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902050-00001

Keywords

Search

Navigation